Boyds reports strong growth despite biotech sector headwinds
Global drug development consultancy Boyds has reported robust revenue growth for the financial year ending March 2026, despite the slowdown in the global biotech and pharma markets.
Established in 2005, Boyds provides specialist consultancy services to an international client base, supporting the development of new, cutting-edge medicines and medical devices for patient benefit.
